<DOC>
	<DOCNO>NCT02982083</DOCNO>
	<brief_summary>The investigator select 40 postmenopausal woman suffer RA 2.5 &lt; DAS28 &lt; 5.5 refer rheumatology clinic Mashhad university medical science randomly divide intervention group placebo group . Evista tab 60mg/day placebo administer double blind . In begin , total bone mineral density ( BMD ) assessment carry patient Alendronate discontinue 2 group . In first 3 month , addition Evista placebo , MTX tab 2.5mg give patient allow consume NSAID accurate record dosage . Patients visit rheumatologist monthly 3 month NSAID discontinue 48 hour every visit . At end month 3 , disease activity probable complication evaluate compare 2 group . Classic regimen start every patient n't enter remission phase first 3 month . In 4th month , DMARD regimen administer patient visit every 2 month . Clinical finding collect month 0 , 1 , 2 , 3 , 6 , 8 , 10 , 12 . After 12 month , another total BMD test carry data analyze include change BMD , DAS28 , EULAR response criterion HAQ-DI score .</brief_summary>
	<brief_title>Clinical Trial Efficacy Raloxifene Disease Activity Rheumatoid Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Raloxifene Hydrochloride</mesh_term>
	<criteria>Patients postmenopausal woman . Patients fit least 4 criterion ACR1987 criterion rheumatoid arthritis . Patients range 2.5 &lt; DAS28ESR &lt; 5.5 Patients history thrombotic event Patients suffer another rheumatic disease simultaneously Patients sever symptom menopause Patients know psychological disease</criteria>
	<gender>Female</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Rheumatoid arthritis</keyword>
	<keyword>Raloxifene</keyword>
	<keyword>Disease activity</keyword>
</DOC>